Bulirsch LM, Saßmannshausen M, Nadal J, et al. - Since brolucizumab has recently been approved in Europe as a novel treatment for patients with neovascular age-related macular degeneration (nAMD), researchers reported on early experiences with real-world outcomes of a switch to brolucizumab therapy in previously anti-vascular endothelial growth factor (anti-VEGF)-treated patients. Sixty-three eyes of 57 patients with nAMD (52.6% females) with a mean (± SD) age of 79.5 ± 6.7 years were involved. According to the findings of the SHIFT study, switching to brolucizumab could be a viable treatment choice for patients with nAMD who have failed to respond to other anti-VEGF agents. Further long-term analyses seem prudent to evaluate the effectiveness and safety of brolucizumab in a routine clinical setting.